This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Craven, P. A. Articles by DeRubertis, F. R. Search for Related Content PubMed PubMed Citation Articles by Craven, P. A. Articles by DeRubertis, F. R.

(Hypertension. 1996;28:169-176.)
© 1996 American Heart Association, Inc.

Articles

Thromboxane/Prostaglandin Endoperoxide–Induced Hypertrophy of Rat Vascular Smooth Muscle Cells Is Signaled by Protein Kinase C–Dependent Increases in Transforming Growth Factor-ß

Patricia A. Craven; Rebecca K. Studer; Frederick R. DeRubertis

the Department of Medicine, VA Medical Center, and University of Pittsburgh (Pa).

Correspondence to Patricia A. Craven, VAMC, University Drive C, Pittsburgh, PA 15240.

In the present study, we examined the effect of the thromboxane/prostaglandin endoperoxide analogue U46619 on proliferation and hypertrophy in cultured rat vascular smooth muscle cells and the roles of protein kinase C and transforming growth factor-ß (TGF-ß) in the mediation of the hypertrophic response to U46619. Since an increase in basic fibroblast growth factor (bFGF) was previously shown to mediate the hypertrophic response to U46619, we also assessed the relationship between bFGF and TGF-ß in the expression of U46619 actions. U46619 increased [³⁵S]methionine incorporation into protein and protein content of vascular smooth muscle cells but had no effect on cell number. A role for TGF-ß was supported by the following observations: (1) exogenous human TGF-ß1 increased protein synthesis; (2) antibody to TGF-ß blocked both TGF-ß– and U46619-induced increases in protein content; (3) U46619 increased active and total TGF-ß bioactivities; and (4) the actions of U46619 on protein content and TGF-ß bioactivity were blocked by the thromboxane/prostaglandin endoperoxide receptor antagonist SQ 29,548. Previous observations had demonstrated a role for bFGF in the expression of U46619 actions on protein synthesis. Results of the present study suggest that TGF-ß and bFGF interact in mediating the protein synthetic response to U46619. First, the concentration of exogenous TGF-ß (10 pmol/L) alone required to produce a protein synthetic response equivalent to that induced by U46619 was much higher than the concentration of endogenous active TGF-ß that accumulated in the media in response to U46619 (0.7 pmol/L). Second, bFGF (20 ng/mL) increased total TGF-ß bioactivity and stimulated protein synthesis. The hypertrophic response to bFGF was blocked by anti–TGF-ß. The ability of U46619 and bFGF to increase protein synthesis and protein content in vascular smooth muscle cells was associated with TGF-ß–induced suppression of proliferation, as evidenced by the ability of antibody to TGF-ß to enhance U46619- and bFGF-induced increases in [³H]thymidine incorporation into DNA. Results of the present study also supported a role for protein kinase C in the expression of U46619 and bFGF actions. U46619 increased protein kinase C activity in the particulate fraction of vascular smooth muscle cells. Moreover, the protein kinase C inhibitors GF109203X and staurosporine blocked U46619- and bFGF-induced increases in protein synthesis as well as active and total TGF-ß bioactivities. By contrast, the protein kinase C inhibitors did not prevent the increases in protein synthesis induced by exogenous TGF-ß. The results demonstrate that thromboxane/prostaglandin endoperoxide signals increased TGF-ß bioactivity via protein kinase C. Increases in both bFGF and TGF-ß are required for an optimal hypertrophic response to U46619. The hypertrophic response to TGF-ß occurs through a protein kinase C–independent pathway.

Key Words: protein kinase C • transforming growth factor beta • fibroblast growth factor, basic • hypertrophy • muscle, smooth, vascular

This article has been cited by other articles:

				I. C. Allen, J. M. Hartney, T. M. Coffman, R. B. Penn, J. Wess, and B. H. Koller Thromboxane A2 induces airway constriction through an M3 muscarinic acetylcholine receptor-dependent mechanism Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L526 - L533. [Abstract] [Full Text] [PDF]

				C. S. Wilcox Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2005; 289(4): R913 - R935. [Abstract] [Full Text] [PDF]

				A. Haider, I. Lee, J. Grabarek, Z. Darzynkiewicz, and N. R. Ferreri Dual Functionality of Cyclooxygenase-2 as a Regulator of Tumor Necrosis Factor-Mediated G1 Shortening and Nitric Oxide-Mediated Inhibition of Vascular Smooth Muscle Cell Proliferation Circulation, August 26, 2003; 108(8): 1015 - 1021. [Abstract] [Full Text] [PDF]

				S. M. Miggin and B. T. Kinsella Regulation of Extracellular Signal-Regulated Kinase Cascades by alpha - and beta -Isoforms of the Human Thromboxane A2 Receptor Mol. Pharmacol., April 1, 2002; 61(4): 817 - 831. [Abstract] [Full Text] [PDF]

				E. Connolly, D. J. Bouchier-Hayes, E. Kaye, A. Leahy, D. Fitzgerald, and O. Belton Cyclooxygenase Isozyme Expression and Intimal Hyperplasia in a Rat Model of Balloon Angioplasty J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 393 - 398. [Abstract] [Full Text] [PDF]

				Y. Shizukuda and P. M. Buttrick Protein kinase C-zeta modulates thromboxane A2-mediated apoptosis in adult ventricular myocytes via Akt Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H320 - H327. [Abstract] [Full Text] [PDF]

				W. Young, K. Mahboubi, A. Haider, I. Li, and N. R. Ferreri Cyclooxygenase-2 Is Required for Tumor Necrosis Factor-{alpha}- and Angiotensin II-Mediated Proliferation of Vascular Smooth Muscle Cells Circ. Res., April 28, 2000; 86(8): 906 - 914. [Abstract] [Full Text] [PDF]